Data Sheet (Cat.No.T24588)

TargetMol

Palatrigine

Chemical Properties



CAS No. : 98410-36-7

Formula: C12H13Cl2N5

Molecular Weight: 298.17

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Palatrigine (BW-A 256C) is a compound with angiotensin-converting enzyme inhibitory and beta-adrenergic receptor blocking properties.
Targets(IC50)	RAAS,Others,Adrenergic Receptor,Angiotensin-converting Enzyme (ACE)
In vitro	BW A256C reduced the maximum rate of depolarization of guinea-pig ventricle and dog Purkinje fibres in vitro (EC50, 2.2 X 10(-6) M and 1.8 X 10(-6) M, respectively).[1]
In vivo	In conscious dogs, BW A256C (1.5 mg/kg; intravenous infusion) or BW A256C (1.25-5 mg/kg;oral administration) caused dose-dependent suppression of the ventricular ectopic activity that occurred following 20-24 h of permanent coronary artery ligation.[1]

Solubility Information

Solubility	DMSO: 25 mg/mL (83.84 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.3538 mL	16.769 mL	33.5379 mL
5 mM	0.6708 mL	3.3538 mL	6.7076 mL
10 mM	0.3354 mL	1.6769 mL	3.3538 mL
50 mM	0.0671 mL	0.3354 mL	0.6708 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Allan G, et al. BW A256C, a chemically novel class 1 antiarrhythmic agent. A comparison of in vitro and in vivo activity with other class 1 antiarrhythmic agents. Br J Pharmacol. 1986;88(2):333-343.

Donoghue S, et al. Effects of BW A256C, a novel class 1 antiarrhythmic agent, on maximum rate of depolarisation of cardiac action potentials in vitro: frequency, use, and voltage dependence. J Cardiovasc Pharmacol. 1987;9(1):12-18.

Allan G, Cambridge D, Hardy GW, Follenfant MJ. BW A575C, a chemically novel agent with angiotensin converting enzyme inhibitor and beta-adrenoceptor-blocking properties. Br J Pharmacol. 1987 Mar;90(3):609-15. PubMed PMID: 2882805; PubMed Central PMCID: PMC1917187.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481